Safety of Medicines - A Guide to Detecting and Reporting Adverse Drug Reactions - Why Health Professionals Need to Take Action
(2002; 16 pages)
Table des matières
Afficher le documentIntroduction
Afficher le documentGlossary
Afficher le documentThe magnitude of the problem
Afficher le documentWhy postmarketing surveillance and reporting ADR is needed
Afficher le documentWhy pharmacovigilance is needed in every country
Afficher le documentHow voluntary reporting on ADRs can prevent new medicine tragedies from developing
Afficher le documentHow voluntary reporting on ADRs can influence labelling
Afficher le documentWhy health professionals are in the best position to detect and report on ADRs
Afficher le documentHow to recognize ADRs
Afficher le documentWhat should be reported?
Afficher le documentHow to report ADRs?
Afficher le documentReferences
Afficher le documentAcknowledgements
 

How to report ADRs?

Local Case Report Forms (CRF) should be obtained from the National Drug Regulatory Authority. Some countries have included CRF in their National Formularies (British National Formulary, Formularies of South Africa, Zimbabwe etc.).

There are different Case Report Forms in different countries. But all of them have at least four sections which should be completed:

1. Patient information:

- patient identifier
- age at time of event or date of birth
- gender
- weight

2. Adverse event or product problem:

- description of event or problem
- date of event
- date of this report
- relevant tests/laboratory data (if available)
- other relevant patient information/history
- outcomes attributed to adverse event

3. Suspected medication (s):

- name (INN and brand name)
- dose, frequency & route used
- therapy date
- diagnosis for use
- event abated after use stopped or dose reduced
- batch number
- expiration date
- event reappeared after reintroduction of the treatment
- concomitant medical products and therapy dates

4. Reporter:

- name, address and telephone number
- speciality and occupation

The completed Case Report Form should be sent to the national or regional ADR centre or to the manufacturer of the suspected product.

Addresses of National Drug Regulatory Authorities and other useful information can be found on the Website of the WHO Collaborating Centre for International Drug Monitoring (www.who-umc.org) or requested from this Centre by e-mail: info@who-umc.org; by Fax: +46 18 65 60 80 or by Tel.: +46 18 65 60 60.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013